Levy Antonin, De Felice Francesca, Bellefqih Sara, Guigay Joël, Deutsch Eric, Nguyen France, Blanchard Pierre, Tao Yungan
Department of Radiation Oncology, Gustave Roussy, Villejuif, Université Paris Sud, France.
Department of Head and Neck Oncology, Gustave Roussy, Villejuif, France.
Head Neck. 2016 Apr;38 Suppl 1:E905-10. doi: 10.1002/hed.24125. Epub 2015 Jul 15.
The purpose of this study was to evaluate the tolerability of concurrent radiotherapy and cetuximab (bioradiotherapy [BRT]) after taxane-based induction chemotherapy in head and neck squamous cell carcinoma (HNSCC).
One hundred four patients with HNSCC received BRT with (29%) or without (71%) prior taxane-based induction chemotherapy.
Radiodermatitis (97%) and skin rash (65%) occurred frequently, but there was no difference of occurrence or the grade of the rash observed in the 2 populations. However, patients receiving taxane-based induction chemotherapy had a less severe rash as compared with patients without induction chemotherapy. Mucositis and dysphagia were frequent and comparable in the 2 groups. The occurrence of a skin rash (at any grade) did not predict an increased overall survival (OS) in the overall population, but it was associated with an improved 3-year OS in patients receiving taxane-based induction chemotherapy. OS was not influenced by the skin rash grade in the overall population of the 2 treatment subgroups.
Taxane-based induction chemotherapy did not increase the rate of cetuximab-related toxicities. © 2015 Wiley Periodicals, Inc. Head Neck 38: E905-E910, 2016.
本研究旨在评估头颈部鳞状细胞癌（HNSCC）患者在接受基于紫杉烷的诱导化疗后同步放疗和西妥昔单抗（生物放疗[BRT]）的耐受性。
104例HNSCC患者接受了BRT，其中29%的患者接受过基于紫杉烷的诱导化疗，71%的患者未接受过。
放射性皮炎（97%）和皮疹（65%）频繁出现，但两组患者皮疹的发生率或严重程度无差异。然而，与未接受诱导化疗的患者相比，接受基于紫杉烷的诱导化疗的患者皮疹较轻。两组患者黏膜炎和吞咽困难发生率较高且相当。皮疹（任何级别）的发生在总体人群中并未预示总生存期（OS）增加，但在接受基于紫杉烷的诱导化疗的患者中，皮疹与3年OS改善相关。在两个治疗亚组的总体人群中，OS不受皮疹严重程度的影响。
基于紫杉烷的诱导化疗并未增加西妥昔单抗相关毒性的发生率。©2015威利期刊公司。《头颈》38：E905 - E910，2016年。
